SANGAMO THERAPEUTICS INC's ticker is SGMO and the CUSIP is 800677106. A total of 197 filers reported holding SANGAMO THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 0.77 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $505,604 | -61.5% | 842,955 | -16.6% | 0.00% | -66.7% |
| Q2 2023 | $1,314,112 | -30.5% | 1,010,855 | -5.8% | 0.00% | -40.0% |
| Q1 2023 | $1,889,633 | -49.6% | 1,073,655 | -10.1% | 0.01% | -50.0% |
| Q4 2022 | $3,748,391 | -29.5% | 1,193,755 | +10.1% | 0.01% | -33.3% |
| Q3 2022 | $5,315,000 | +119.2% | 1,084,655 | +85.2% | 0.02% | +114.3% |
| Q2 2022 | $2,425,000 | -26.4% | 585,755 | +3.3% | 0.01% | -22.2% |
| Q1 2022 | $3,293,000 | -43.4% | 566,855 | -26.9% | 0.01% | -40.0% |
| Q4 2021 | $5,817,000 | -32.9% | 775,655 | -19.4% | 0.02% | -31.8% |
| Q3 2021 | $8,668,000 | -29.2% | 962,055 | -6.0% | 0.02% | -31.2% |
| Q2 2021 | $12,247,000 | -30.5% | 1,023,155 | -27.2% | 0.03% | -33.3% |
| Q1 2021 | $17,609,000 | -20.2% | 1,405,355 | -0.6% | 0.05% | -18.6% |
| Q4 2020 | $22,060,000 | +71.2% | 1,413,655 | +3.7% | 0.06% | +59.5% |
| Q3 2020 | $12,888,000 | +30.4% | 1,363,855 | +23.7% | 0.04% | +27.6% |
| Q2 2020 | $9,880,000 | +415.9% | 1,102,655 | +266.8% | 0.03% | +314.3% |
| Q1 2020 | $1,915,000 | +35.3% | 300,655 | +77.8% | 0.01% | +133.3% |
| Q4 2019 | $1,415,000 | -33.4% | 169,055 | -14.3% | 0.00% | -40.0% |
| Q2 2019 | $2,125,000 | -0.5% | 197,300 | -11.9% | 0.01% | 0.0% |
| Q1 2019 | $2,136,000 | -8.5% | 223,900 | +10.1% | 0.01% | -16.7% |
| Q4 2018 | $2,334,000 | +33.7% | 203,300 | +97.4% | 0.01% | +50.0% |
| Q3 2018 | $1,746,000 | -10.3% | 103,000 | -24.9% | 0.00% | -20.0% |
| Q2 2018 | $1,947,000 | -58.3% | 137,100 | -44.2% | 0.01% | -61.5% |
| Q1 2018 | $4,667,000 | -2.0% | 245,655 | -15.4% | 0.01% | 0.0% |
| Q4 2017 | $4,764,000 | +1002.8% | 290,479 | +908.6% | 0.01% | +1200.0% |
| Q3 2017 | $432,000 | +1100.0% | 28,800 | +144.1% | 0.00% | – |
| Q4 2016 | $36,000 | -83.0% | 11,800 | -67.7% | 0.00% | -100.0% |
| Q2 2016 | $212,000 | +118.6% | 36,555 | +128.5% | 0.00% | 0.0% |
| Q1 2016 | $97,000 | +4.3% | 16,000 | +57.6% | 0.00% | 0.0% |
| Q4 2015 | $93,000 | -62.7% | 10,155 | -37.9% | 0.00% | -50.0% |
| Q4 2014 | $249,000 | +43.9% | 16,355 | +1.9% | 0.00% | +100.0% |
| Q3 2014 | $173,000 | -54.0% | 16,055 | -34.9% | 0.00% | -66.7% |
| Q2 2014 | $376,000 | – | 24,655 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Golden State Equity Partners | 154,360 | $897,000 | 0.45% |
| Rhenman & Partners Asset Management AB | 761,429 | $4,424,000 | 0.44% |
| Lombard Odier Asset Management (Switzerland) SA | 860,702 | $5,001,000 | 0.39% |
| WASATCH ADVISORS LP | 10,576,997 | $61,452,000 | 0.30% |
| Rokos Capital Management LLP | 977,663 | $5,861,000 | 0.27% |
| KLK CAPITAL MANAGEMENT LLC | 44,323 | $258,000 | 0.26% |
| Long Focus Capital Management, LLC | 340,000 | $1,975,000 | 0.25% |
| Vanguard Capital Wealth Advisors | 33,380 | $193,000 | 0.14% |
| Fort Sheridan Advisors LLC | 73,978 | $430,000 | 0.13% |
| Delphia (USA) Inc. | 20,983 | $122,000 | 0.09% |